Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Contact information


rachel.dunn@oncology.ox.ac.uk

Rachel Austin

BA(Hons) MSc

Trial Manager

I joined the Oncology Clinical Trials Office (OCTO) in December 2018 as a Clinical Trials Administrator, mainly working on the OCTOVA study. I joined OCTO from the NHS, where I previously worked at the Warneford and John Radcliffe Hospitals. In 2022, I was promoted to Trial Manager within OCTO and have worked on PanDox and SCOOT, as well as supporting archiving for older trials in the portfolio.

My current role involves working with a wide variety of people: leading the immediate trial team, supporting clinical staff at study sites, reporting to the study funders and updating external collaborators. A Trial Manager has a large number of study responsibilities including protocol preparation/amendment, regulatory submissions, sample oversight, drug management, stakeholder communication, and timeline management.

Trials I am currently working on:

  • SCOOT - This study aims to use blood biomarkers to support quicker and more accurate diagnosis of lung cancers by developing an algorithm which may be used on its own, or in combination with CT scan images. 

Publications: 

  • Randomised Phase II Trial of Olaparib, chemotherapy, or Olaparib and Cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol (https://www.oncology.ox.ac.uk/publications/1149973)
  • Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox) and focused ultrasound (https://bmccancer.biomedcentral.com/articles/10.1186/s12885-023-11228-z)